Physician profile
Matthew Summers
NPI 1942381710
$3,345.92
in general payments reported to CMS, 2019-2025
25 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $176 · 2021: $262 · 2022: $461 · 2023: $247 · 2024: $1,292 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,535 · Travel and Lodging: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,535.36 |
| Travel and Lodging | $447.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $902.91 | 2024 | Navitor |
| Astrazeneca Pharmaceuticals Lp | $518.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.38 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $297.24 | 2021-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $284.08 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $224.59 | 2021-2024 | Vraylar |
| Pfizer INC. | $111.92 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.19 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $79.67 | 2019-2023 | |
| Astellas Pharma US INC | $72.30 | 2019-2024 | Veozah |
| Allergan, INC. | $69.61 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $59.65 | 2023-2025 | Rexulti |
| Amgen INC. | $59.54 | 2020-2025 | Evenity, Prolia, Prolia |
| Janssen Pharmaceuticals, INC | $53.53 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $33.20 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $29.83 | 2022 | |
| Merck Sharp & Dohme LLC | $25.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.66 | 2019-2022 | |
| Organogenesis INC. | $24.18 | 2022 | |
| Seqirus USA INC | $19.48 | 2025 | Fluad, Flucelvax |
| Philips North America LLC | $16.66 | 2019 | |
| Medtronic, INC. | $14.78 | 2022 | |
| Dexcom, INC. | $14.57 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.67 | 2020 | |
| Glaxosmithkline, LLC. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Summers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.